Zhitong Finance App News, Sihuan Pharmaceutical (00460) issued an announcement. Recently, Qiyan Space Biotechnology (Jilin) Co., Ltd. (Qiyan Space), a subsidiary of the Group, has completed a strategic equity investment in Guangzhou Hanteng Biotechnology Co., Ltd. (Hanteng Biology). At the same time, the two sides plan to carry out joint commercial cooperation around the commercial sale of Hanteng Biotech's full-length three-helix recombinant human collagen raw material (this raw material). Based on this raw material, Beauty Space will develop a series of collagen medical and aesthetic formulation products to improve the Group's regenerative medicine and aesthetic business layout.
Hanteng Biotech has multiple biomanufacturing technology platforms such as CHO cells, prokaryotic fermentation, and virus expression. The production system is complete, and it has industrial synergy with the Group's medical, aesthetic, and pharmaceutical business. This strategic investment in Hanteng Biotech and the promotion of joint commercial cooperation between the two sides is a key strategic layout for the Group's medical and aesthetic sector to extend to the upstream core biomaterials field. It is of great significance to the Group's deep cultivation of the regenerative medicine and aesthetic circuit, which is mainly reflected in four major dimensions:
1. Lock in the supply of scarce upstream core raw materials and break the technical bottleneck in the industry: obtain a stable supply of full-length recombinant human type III collagen with a complete three-helix structure, break the bottleneck of raw materials commonly used by the industry in fragmented collagen and animal-derived collagen, and consolidate the raw material advantages of beauty space in regenerative medicine and beauty circuits.
2. Open up a complete industrial chain of “upstream raw materials - formulation development - terminal commercialization” and build barriers to industrial competition: deeply bind the source of technology through equity investment; the two sides plan to promote the marketing and sales of this raw material through a cooperative model, and Huiyan Space undertakes medical and aesthetic formulation research and development, registration and declaration work to achieve a closed loop implementation from biological raw materials to terminal medical and aesthetic products.
3. Strengthen the Group's differentiated competitive advantage in regenerative medicine and meet industry trends: The Group grasps technology upgrading trends in the recombinant collagen industry, actively lays out high-end recombinant human collagen (different from recombinant humanized fragment collagen) defined by the State Drug Administration's “Guidelines for Nomenclature of Recombinant Collagen Biomaterials”, accurately matches high-end medical and aesthetic consumption needs, and helps the Group further expand the domestic high-end regenerative medicine and aesthetic market.
4. Achieve complementary industrial resources and win-win development: This cooperation gives full play to the respective resource advantages of both parties. Hanteng Biotech relies on the technical advantages of its CHO cell expression platform and large-scale GMP production advantages; Huiyan Space leverages its capabilities in medical and aesthetic product research and development, registration, channel layout, and brand commercialization. The two sides jointly helped industrialize domestic full-length three-helix recombinant human collagen technology and promote the high-quality development of the industry.
Recombinant collagen is a core biomaterial in the field of regenerative medicine and aesthetics. The domestic market is growing rapidly. The domestic recombinant collagen market is expected to exceed RMB 100 billion in 2027. With the implementation of the State Drug Administration's “Guiding Principles for Nomenclature of Recombinant Collagen Biomaterials”, the industry regulatory system continues to standardize, and the government clearly divides recombinant collagen into three categories: recombinant human collagen (full length, high homologous, stable three-helix structure), recombinant collagen (low homology, generally not having a triple helix structure). Among them, recombinant human collagen with full length, high homology, and a stable three-helix structure fits the mainstream direction of industry technology upgrading and market consumption iteration, and is currently a key development product type in the field of high-end regenerative medicine and aesthetics.
The full-length three-helix recombinant human collagen laid out by the Group has better product characteristics and technical advantages. It is highly homologous to the amino acid sequence of natural human collagen, has a complete structure and stable performance, and has outstanding biological activity in scenarios such as cell repair, tissue regeneration, and skin anti-aging. It can be widely used in high-end medical and aesthetic fields. It has great commercial value and market prospects, can effectively enrich the Group's high-end medical and aesthetic product matrix, and continuously enhance the Group's comprehensive competitiveness in the field of regenerative medicine and aesthetics.